Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.21 USD | -0.26% | -6.34% | -10.48% |
05-08 | Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating | MT |
05-08 | Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.48% | 2.75B | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Says Takeda to Co-Develop, Co-Commercialize DNL593 Frontotemporal Dementia Investigational Therapy